Haisco Pharmaceutical progresses with A-share offering for R&D

Haisco Pharmaceutical Group’s A-share offering, sponsored by CITIC Securities, targets up to 35 specific investors, with the final price determined by competitive bidding. The company has secured necessary approvals from its board and shareholders for the offering, which totals up to 124,525.67 million yuan for new drug R&D and working capital. The offering is anticipated to close within six months of regulatory approval.

The company has updated its financial data to H1 2025, revealing total assets of 699,164.61 million yuan, operating income of 200,084.45 million yuan, and net profit attributable to shareholders of 12,882.20 million yuan. Haisco Pharmaceutical noted that its capital expenditure for new drug R&D accounts for 70.46% of the total raised, with 29.54% allocated to working capital, aligning with regulatory requirements.

The offering remains subject to further review by the Shenzhen Stock Exchange and registration with the China Securities Regulatory Commission. Wang Junmin, the controlling shareholder, has pledged continued commitment to the company's growth.